Partial efficacy of low-dose naltrexone in post-orgasmic illness syndrome with lichen sclerosus: a case report
Clinical and Experimental Dermatology · 10.04.2026
DOI: 10.1093/ced/llag152 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 10.04.2026. Verfasst von John Han Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospitals NHS Foundation Trust, UK. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
We report a patient with a symptom history consistent with post-orgasmic illness syndrome (POIS) and male genital lichen sclerosus (MGLSc), and to our knowledge, the first published case of a patient presenting with these conditions, both of which have been associated with sexual dysfunction. The patient’s POIS symptoms persisted despite MGLSc resolution post-circumcision. We report that naltrexone provided partial symptom relief for his symptoms, offering a potential novel treatment approach.
Autor:innen und Institutionen
- University College London Hospitals NHS Foundation Trust, UK.
- University College London, UK.
Zitieren
APA
Ye, J. H., Choudhary, C., Rees, R. W., Brockbank, B., Kravvas, G., & Bunker, C. B. (2026). Partial efficacy of low-dose naltrexone in post-orgasmic illness syndrome with lichen sclerosus: a case report. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag152
Vancouver
Ye JH, Choudhary C, Rees RW, Brockbank B, Kravvas G, Bunker CB. Partial efficacy of low-dose naltrexone in post-orgasmic illness syndrome with lichen sclerosus: a case report. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag152
BibTeX
@article{Ye2026,
author = {Ye, John Han and Choudhary, Cherry and Rees, Rowland W and Brockbank, Bethany and Kravvas, Georgios and Bunker, Christopher B},
title = {Partial efficacy of low-dose naltrexone in post-orgasmic illness syndrome with lichen sclerosus: a case report},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag152}
}
EUVIMED